Company

Semafore Pharmaceuticals is a clinical-stage drug discovery and development company focused on small molecule modulators of the PI3 kinase (PI3K) and PTEN cell signaling pathway, a promising target pathway for multiple disorders, including the company’s focus-- Cancer.

Semafore is one of the first biopharmaceutical companies to focus on both PI3K and PTEN and has successfully discovered and is developing a portfolio of drug candidates addressing these targets.